Clarxon Disease (Capillary leak syndrome)

Main Article Content

Maha khalaf Ali Aljuboury
Fatma Qassim Mohammed

Abstract

     Capillary leak syndrome (CLS) is a challenging and even fatal disorder that is becoming more widely known (CLS). After the initial hazy symptoms, the interesting The dual paradox of broad severe edema & hypovolemia, as well as hemoconcentration and hypoalbuminemia, which is a characteristic of CLS, manifests. . A poor outcome during The iatrogenic fluid surplus during the leak phase is often linked to the spontaneous resolutive phase. The main causes of CLS are malignancy, viruses, inflammatory diseases, medications (anti-tumoral therapy), and malignancy. In honor of its discoverer, the idiopathic variety is known as Clarkson's disease. A substantial, transient, and complex endothelium disruption, the mechanisms of which are now unclear, is a component of CLS' pathogenesis. Empirical and experience-based therapy consists of pharmacological treatment during the acute stage (perhaps with the addition of medication) that increase rates of cyclic adenosine monophosphate (cAMP) in the most severe patients), for avoiding relapses with monthly administration of adaptable immunoglobulins. Due to the scattered nature of the CLS literature, we set out to gather and summarize the most recent studies on the condition in order to help in its identification, comprehension, and treatment.

Article Details

How to Cite
[1]
“Clarxon Disease (Capillary leak syndrome)”, JUBPAS, vol. 31, no. 4, pp. 207–216, Jan. 2024, doi: 10.29196/0gnf7r98.
Section
Articles

How to Cite

[1]
“Clarxon Disease (Capillary leak syndrome)”, JUBPAS, vol. 31, no. 4, pp. 207–216, Jan. 2024, doi: 10.29196/0gnf7r98.

Similar Articles

You may also start an advanced similarity search for this article.